thought post call
despit solid biktarvi beat remain cautiou outlook
gilead see sign weak hiv portfolio gilead beat
top bottom line descovi odefsey genvoya truvada miss
expect under-perform off-set biktarvi sale significantli
expect well resili across portfolio intern
market howev continu believ biktarvi opportun well-
understood investor believ biktarvi out-performance
alon enough drive share current level continu weak
may caus shift investor focu pipelin replenish resili
base busi rais biktarvi estim throughout
forecast lower estim genvoya odefsey truvada
descovi forecast modestli lower well continu believ
prep under-penetrated still underappreci investor
reduc tp reiter neutral rate
recent deal galapago provid pipelin option cost
continu believ deal galapago more-than- valu
us ipf oa opportun given remain clinic risk
reduc econom gilead exclus option galapago
develop pipelin could provid upsid assign valu asset
given undisclos mechan target encourag
gilead demonstr willing larger deal need see
execut bd front fulli comfort capit
valuat model chang tp base sum-of-the-part
sotp dcf analysi assum wacc tvgr
forecast ep driven
approv product commerci product may sell well
anticip price legisl may put pressur drug price market
risk biotech volatil sector
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
inc biopharmaceut compani
engag research develop commerci
medicin area infecti diseas oncolog immunolog
area unmet medic need
price jul rate neutral target price analyst evan seigerman
profit tax
associ
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
sky scenario model probabl success
yescarta expans well filgotinib also assum
success mid-stag nash asset exclud selonsertib
maintain base case third line yescarta hiv hcv sale
grey sky scenario model car-t platform
success beyond dlbcl filgotinib program delay
fail meet base-cas expect nash program fail
maintain base case third line yescarta hiv hcv sale
 close
pipelin updat regard filgotinib gilead still track submit nda
rheumatoid arthriti fda gilead plan initi phase studi
psoriat arthriti filgotinib look filgotinib compani expect data
selction phase studi ulcer coliti initi phase studi
ankylos spondyl also complet enrol divers phase
crohn diseas hiv franchis gilead expect data phase
studi nrti still track potenti approv descovi
prep submiss eu expect toledo updat
galapago partnership
model adjust increas biktarvi estim
base better-than-expect sale rais biktarvi estim
throughout forecast project sale given
lower-than-expect sale genvoya lower near-term expect
also lower estim truvada
odefsey descovi follow lower-
than-expect hiv franchis sale assumpt cog sg
mostli unchang minor adjust driven margin assumpt result
forecast non-gaap ep figur
figur gilead quarterli annual ep usd
profit loss tax
cog revenu
 revenu
sg revenu
charl martineau pm univers toronto compani mention price
